Myelodysplastic Syndrome Information

Nplate® and Vidaza® Effective for Low- and Intermediate-risk MDS (1/5/2009)
Researchers involved in a U.S. multicenter trial have reported that the combination of Nplate® (romiplostim) and Vidaza® (azacytidine) is effective and well tolerated in patients with low- and intermediate-risk myelodysplastic symdrome. The details of this Phase II study were presented on December 8, 2008 at the 2008 meeting of the American Society of Hematology.

Few Patients with Myelodysplastic Syndromes Entered on Clinical Trials (11/18/2008)
Researchers from the Cleveland Clinic, M. D. Anderson Cancer Center, the H. Lee Moffitt Cancer Center, and Amgen Inc. have reported that only 4% of patients with myelodysplastic syndromes (MDS) were treated on clinical trials. The details of this study appeared in the November 5, 2008 issue of the Journal of the National Cancer Institute.

Vidaza® Improves Survival of Higher-Risk Myelodysplastic Syndromes (MDS) (1/2/2008)
Researchers affiliated with the AZA-001 study have reported that Vidaza (azacitadine) prolongs survival of patients with higher risk myelodysplastic syndrome (MDS). The details of this randomized study were presented at the 2007 meeting of the American Society of Hematology in Atlanta, Georgia in December.

Romiplostim (AMG 531) for Treatment of Thrombocytopenia in MDS (12/27/2007)
Researchers affiliated with The AMG 531 Myelodysplastic Syndrome Study Group have reported that romiplostim (AMG531) can reduce bleeding and transfusion events in patients with myelodysplastic syndromes (MDS). The details of this study were presented at the 2007 meeting of the American Society of Hematology (ASH), December 8-11, 2007 in Atlanta, Georgia.

Umbilical Cord Blood Transplantation with Reduced Intensity Regimen Effective (11/14/2007)
Researchers from the University of Minnesota have reported that adults with hematological diseases have a three year survival of almost 50% following umbilical cord blood transplantation after a reduced intensity treatment regimen. The details of this study appeared in the October 15, 2007 issue of Blood.